Abbott Laboratories (ABT) Return on Investment ROI from the first quarter of 2026 to first quarter of 2025 and for the year 2026, average high and low, overall ranking from Mar 31 2026 to Mar 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Abbott Laboratories  (NYSE: ABT)


Abbott Laboratories's ROI from its first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Abbott Laboratories's ROI in the first quarter of 2026?
Abbott Laboratories achieved a return on average invested assets (ROI) of 9.03 % in its first quarter of 2026, which is below Abbott Laboratories's average return on investment, which stands at 10.3%.

ROI decreased relative to the period ending Dec 31 2025, due to the decline in net income.

Within the Healthcare sector 130 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the fourth quarter of 2025 from 638 to 1015.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Investment Change TTM 18.51 % 14.57 % 18.36 % 14.06 % 9.3 %
Y / Y Net Income Change TTM -53.52 % -51.32 % 234.94 % 453.19 % 1002.2 %
Investment (TTM) in Millions 82,979 67,761 63,170 64,023 62,053
Return On Investment (TTM) 9.03 % 10.15 % 21.87 % 22.77 % 23.03 %
ABT's Overall Ranking # 1015 # 638 # 253 # 218 # 243
Seq. Investment Change TTM 8.14 % 0.52 % 4.11 % 4.73 % 4.55 %
Seq. Net Income Change TTM -3.8 % -53.32 % -0.01 % 3.53 % 0.75 %
Net Income (TTM) in Millions 6,276 6,524 13,977 13,979 13,502

ABT Company Profile >> Back to ABT Roi Comparisons >> See Annual ABT Return On Investment



Return On Investment ABT's Ranking
Within: No.
Industry # 52
Sector # 131
Overall # 1015

Return On Investment Statistics
High Average Low
22.57 %
10.3 %
0.73 %
(Dec 31 2024)   (Dec 31 2017)







Financial Statements
Abbott Laboratories's I. Quarter Investments $ 82,979 Millions ABT's Balance sheet
Abbott Laboratories's I. Quarter Income $ 1,077 Millions Quarterly ABT's Income Statement
ABT's Income by Division See ABT's Income by Division


ABT Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 67,761 66,441 58,143 51,646 53,542
Y / Y Investment Growth 1.99 % 14.27 % 12.58 % -3.54 % 3.46 %
Net Income in Millions 6,524 13,402 5,723 6,933 7,071
Y / Y Net Income Growth -51.32 % 134.18 % -17.45 % -1.95 % 57.31 %
Annual Return On Investment 9.63 % 20.17 % 9.84 % 13.42 % 13.21 %


Annual Roi Comment
In the fiscal year 2025 ROI decreased relative to the previous year to 9.63 %, due to deterioration of net income.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ABT's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ABT's Competitors
Subscribers only: Roi for Abbott Laboratories's Suppliers
Subscribers only: Return On Investment for ABT's Customers

Other Ratios
ABT's Roa ABT's Inventory Turnover Ratio ABT's Growth Rates ABT's Dividend Statistics
ABT's Profitability Ratios ABT's Asset Turnover Ratio ABT's Dividend Growth
ABT's Roe ABT's Valuation Ratios ABT's Financial Strength Ratios ABT's Dividend Payout Ratio



Companies with similar Return On Investment at Mar 31 2026, within Healthcare Sector ROI
Carlisle Companies Incorporated  24.39 %
Iradimed Corporation  23.59 %
Catalyst Pharmaceuticals Inc   23.58 %
Engene Therapeutics Inc   22.76 %
Protalix Biotherapeutics inc   22.70 %
Electromed Inc   22.36 %
Dexcom Inc   22.17 %
Illumina Inc   22.01 %
Pro dex Inc   20.88 %
Gilead Sciences Inc   20.52 %
Vertex Pharmaceuticals Inc  20.49 %
Agilent Technologies inc   20.46 %
Zoetis Inc   20.35 %
Resmed Inc   20.23 %
Soleno Therapeutics Inc  19.51 %
Krystal Biotech Inc   19.07 %
Puma Biotechnology Inc   18.83 %
United Therapeutics Corporation  18.64 %
Hca Healthcare Inc   18.54 %
Chemed Corporation  18.36 %
Apellis Pharmaceuticals Inc   17.94 %
Neurocrine Biosciences Inc   17.65 %
Halozyme Therapeutics Inc   17.53 %
Transmedics Group Inc   17.09 %
Inspire Medical Systems inc   16.60 %
Aveanna Healthcare Holdings Inc   16.38 %
Intuitive Surgical Inc   16.36 %
Alnylam Pharmaceuticals Inc   16.15 %
Strata Critical Medical Inc   16.15 %
Standard Biotools Inc   15.94 %

Date modified: 2026-09-26T07:14:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.